4月25日,据CDE官网消息,基石药业(苏州)有限公司、无锡药明合联生物技术有限公司联合申请药品“注射用CS5001”,获得临床试验默示许可,受理号CXSL2500169。公示信息显示,药品“注射用CS5001”适应症:联合当前标准治疗药物R-GemOx方案(利妥昔单抗, 吉西他滨, 奥沙利铂),R2方案(利妥昔单抗,来那度胺)和R-CHOP方案(利妥昔单抗,环磷酰胺,多柔比星,长春新碱,泼尼松)...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.